Shanghai kaibao company honor

Since 200 1, Shanghai Kaibao Pharmaceutical Co., Ltd. has been recognized as a high-tech enterprise in Shanghai by Shanghai Science and Technology Commission for nine consecutive years. And was rated as an excellent science and technology enterprise in Fengxian District; Shanghai patent pilot enterprise, Shanghai brand enterprise, Shanghai little giant enterprise (cultivation type), A-level tax credit enterprise, AAA-level contract credit enterprise, advanced unit of price integrity and self-discipline, top 100 enterprises of high-tech achievements transformation project in Shanghai, and top 10 enterprises of independent innovation in Shanghai. At present, there are 704 employees in the company, of whom college degree or above accounts for more than 36%.

Shanghai Kaibao Pharmaceutical Co., Ltd. has 20 Chinese and western medicine approval numbers, including high-tech products such as slow-release and controlled-release agents, which are divided into cardiovascular and cerebrovascular, antiviral and respiratory systems. The leading product is Tanreqing injection, a second-class traditional Chinese medicine, which is a patented new product with independent intellectual property rights. It was developed by Shanghai Kaibao Pharmaceutical Co., Ltd. for eight years and invested hundreds of millions of yuan. It was put into production in 2003.

Tanreqing injection developed and produced by Shanghai Kaibao Pharmaceutical Co., Ltd. won the National Development and Reform Commission's "National Modern Chinese Medicine High-tech Industrialization Demonstration Project"; Shanghai key anti-SARS products; "Famous products in Shanghai pharmaceutical industry", Shanghai high-tech achievements (a) transformation project, and innovation fund support project of Ministry of Science and Technology; Shanghai Science and Technology Progress Third Prize; National Development and Reform Commission's Catalogue of Reserved Chinese Patent Medicines for Influenza Prevention and Reserved Drugs for Influenza Prevention; Shanghai brand products; Shanghai patented new products; Top 100 projects of transformation of scientific and technological achievements and top 10 projects of independent innovation in Shanghai; "Shanghai famous brand products"; It was listed as "Human Avian Influenza Diagnosis and Treatment Program" by the Ministry of Health; In 2009, it was listed by the Ministry of Health and state administration of traditional chinese medicine as "Clinical Technical Guide for Prevention and Treatment of Hand, Foot and Mouth Disease with Traditional Chinese Medicine" and "A H 1N 1 Influenza Diagnosis and Treatment Scheme (2nd Edition, Trial Edition, 2009)". Tanreqing injection has been widely recognized by doctors and patients, and has become a well-known product brand, and its market performance is in a leading position among similar products.